Create issue ticket

113 Possible Causes for mepolizumab

  • Hypereosinophilic Syndrome

    Efficacy of Mepolizumab Treatment.[] We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab[] To analyze the effect of mepolizumab in children is the aim of this study.[]

  • Churg-Strauss Syndrome

    Half received mepolizumab injections and half received placebo once every four weeks for 52 weeks.[] "Patients receiving mepolizumab cut steroid doses and relapses in half," said Dr. Wechsler. "That is a breakthrough for those patients."[] The hypothesis of this study is, that mepolizumab will induce remission and allow for steroid reduction.[]

  • Eosinophilic Endomyocardial Disease

    For example, eosinophilic granulomatosis with polyangiitis can be successfully treated with mepolizumab.[] "Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab" . Retrieved 2008-03-17 .[] The use of antibodies against interleukin‐5 (IL‐5) (mepolizumab), the IL‐5 receptor (benralizumab), and CD52 (alemtuzumab), as well as other targets on eosinophils remains[]

  • Loeffler Endocarditis

    Since mepolizumab inhibits interleukin-5 and has a long terminal halflife, treatment with mepolizumab causes a sustained reduction in the numbers of circulating eosinophils[] For example, eosinophilic granulomatosis with polyangiitis can be successfully treated with mepolizumab.[] Several therapies are currently under investigation as potential HES therapies, like Mepolizumab, a fully humanized monoclonal IgG anti-IL5 antibody.[]

  • Idiopathic Hypereosinophilic Syndrome

    Efficacy of Mepolizumab Treatment.[] At 7 months from diagnosis, IV mepolizumab 750 mg every 4 weeks was started.[] Treatment of patients with Hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2006;358:1215–28. CrossRef Google Scholar 16. Cools J, DeAngelo DJ, Gotlib J.[]

  • Nasal Polyp

    […] said Steve Yancey, vice president and medicine development leader for mepolizumab.[] About mepolizumab Mepolizumab is a targeted anti-IL-5 monoclonal antibody.[] GlaxoSmithKline has kicked off a Phase III study exploring the potential of its biologic mepolizumab in patients with severe bilateral nasal polyps, a chronic inflammatory[]

  • Esophagitis

    KEYWORDS: Eosinophilic esophagitis (EoE); biologics; dupilumab; food-elimination diet; mepolizumab; proton pump inhibitor (PPI); reslizumab; swallowed corticosteroids[] Mepolizumab: 240563, anti-IL-5 monoclonal antibody — GlaxoSmithKline, anti-interleukin-5 monoclonal antibody — GlaxoSmithKline, SB 240563.[] Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomized, placebo-controlled, double-blind trial.[]

  • Asthma

    It will join Nucala, (mepolizumab), Cinqair (reslizumab), and Fasenra (benralizumab) as a monoclonal antibody approved as a treatment for the type 2 inflammation phenotype[] The combination of reslizumab with mepolizumab and benralizumab, which also target IL-5, may be a useful addition to the therapeutic armamentarium in a selected group of patients[] Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic[]

  • Chronic Eosinophilic Leukemia

    Two of these are Alemtuzumab and Mepolizumab, both of which are humanized monoclonal antibodies.[] Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008 ; 358 : 1215 –28. View Abstract[] In patients with no response to these agents, use experimental treatments (mepolizumab, alemtuzumab) or consider allogeneic hematopoietic stem cell transplantation.[]

  • Myeloid Neoplasm Associated with PDGFRB Rearrangement

    Justin Mulvey , Cynthia Magro , Amy Chadburn , Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed[] Preclinical efficacy and safety of mepolizumab (SB – 240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys .[] Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes . J Allergy Clin Immunol 2013 ; 131 : 461 – 467 61.[]

Further symptoms